Matches in Wikidata for { <http://www.wikidata.org/entity/Q92273161> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q92273161 description "clinical trial" @default.
- Q92273161 description "ensayo clínico" @default.
- Q92273161 description "ensayu clínicu" @default.
- Q92273161 description "klinisch onderzoek" @default.
- Q92273161 description "клінічне випробування" @default.
- Q92273161 description "临床试验" @default.
- Q92273161 name "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy" @default.
- Q92273161 name "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy" @default.
- Q92273161 type Item @default.
- Q92273161 label "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy" @default.
- Q92273161 label "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy" @default.
- Q92273161 prefLabel "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy" @default.
- Q92273161 prefLabel "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy" @default.
- Q92273161 P1050 Q92273161-70C37A4F-F1EC-40D8-9F9E-E7E2E99E1851 @default.
- Q92273161 P1132 Q92273161-E18F6C65-845A-4E0B-81A6-4DA1B2C21A90 @default.
- Q92273161 P1476 Q92273161-737BAD28-8A42-4FAA-8AD3-265ABA0C8D7B @default.
- Q92273161 P17 Q92273161-CBEFB27B-3773-4B67-A1C3-494ABE60D087 @default.
- Q92273161 P2899 Q92273161-A5537234-0173-4F11-A90F-26FACC50FB82 @default.
- Q92273161 P3098 Q92273161-B9F05ED9-ADBD-4407-AB54-B1E959F7BD61 @default.
- Q92273161 P31 Q92273161-01E66243-EC70-4B10-8901-92568B981CBB @default.
- Q92273161 P4844 Q92273161-54A8EC98-A8E6-4DE4-A437-478DB1E4D5D7 @default.
- Q92273161 P580 Q92273161-DE3AF302-9AF4-455D-A65A-D63DD95DFBC0 @default.
- Q92273161 P582 Q92273161-E4C06039-AADA-446B-BDAE-823218285525 @default.
- Q92273161 P6099 Q92273161-90082129-7753-4325-A17C-9CE655495D7B @default.
- Q92273161 P767 Q92273161-365EB01F-9C8C-4037-BCFA-CE4F16E72AD9 @default.
- Q92273161 P8005 Q92273161-51E281A7-37A0-4DCB-82F3-3476E5228F96 @default.
- Q92273161 P8363 Q92273161-28971AD4-8DC6-4E02-AA16-2B396FE53A4B @default.
- Q92273161 P1050 Q208414 @default.
- Q92273161 P1132 "+25" @default.
- Q92273161 P1476 "Phase 2 Pilot Study to Evaluate Efficacy and Safety of Anakinra to Prevent CD19-Targeted CAR-T Cell-Related Cytokine Release Syndrome (CRS) and Neurotoxicity in Patients With B Cell Lymphoma" @default.
- Q92273161 P17 Q30 @default.
- Q92273161 P2899 "+18" @default.
- Q92273161 P3098 "NCT04359784" @default.
- Q92273161 P31 Q30612 @default.
- Q92273161 P4844 Q415411 @default.
- Q92273161 P580 "2020-05-30T00:00:00Z" @default.
- Q92273161 P582 "2021-12-31T00:00:00Z" @default.
- Q92273161 P6099 Q42824440 @default.
- Q92273161 P767 Q664846 @default.
- Q92273161 P8005 Q76649614 @default.
- Q92273161 P8363 Q78089383 @default.